Please note this webinar is postponed until further notice.
About the Webinar:
Adverse drug events will cost the Canadian health-care system about $17.7 billion in the coming year, and cause over 22,000 deaths. The Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM) responds to drug safety and effectiveness concerns using real-world cohort data, including CanPath’s.
Already, CanPath data has been used by CAN-AIM to study uncomplicated hypertension monotherapy, therapy options for type 2 diabetes, and other important topics.
About the Speaker: Dr. Sasha Bernatsky
Sasha is a James McGill Professor of Medicine and nominated Principal Investigator of the Canadian Network for Advanced Interdisciplinary Methods for comparative effectiveness research (CAN-AIM). This national team provides novel, accurate data on long-term, real-world outcomes related to drug therapies for the Drug Safety and Effectiveness Network (DSEN), a joint initiative between the CIHR and Health Canada.
Working closely with Health Canada’s Marketed Health Products Directorate and other knowledge users, CAN-AIM produces highly relevant and timely studies of a wide range of high-priority drug safety and effectiveness topics. These have included osteoporosis, chronic hepatitis C, retinal disease, diabetes, hypertension, and many more areas where drug therapy is complex and often plagued by serious adverse events. CAN-AIM also provides career advancement opportunities for graduate and post-graduate students. Through its vision and leadership, CAN-AIM is making essential contributions to building research capacity and forming future experts and leaders in drug safety and effectiveness research in Canada.